Dexcom (DXCM) EVP Richard Doubleday Sells 2,581 Shares

Dexcom (NASDAQ:DXCM) EVP Richard Doubleday sold 2,581 shares of the company’s stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $98.58, for a total transaction of $254,434.98. Following the completion of the transaction, the executive vice president now owns 94,429 shares in the company, valued at approximately $9,308,810.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Richard Doubleday also recently made the following trade(s):

  • On Wednesday, May 23rd, Richard Doubleday sold 2,581 shares of Dexcom stock. The stock was sold at an average price of $86.00, for a total transaction of $221,966.00.
  • On Monday, April 23rd, Richard Doubleday sold 2,581 shares of Dexcom stock. The stock was sold at an average price of $73.09, for a total transaction of $188,645.29.

Shares of Dexcom opened at $95.30 on Wednesday, according to Marketbeat. The company has a debt-to-equity ratio of 0.79, a current ratio of 5.83 and a quick ratio of 5.42. The firm has a market capitalization of $8.41 billion, a PE ratio of -164.31 and a beta of -0.01. Dexcom has a 1 year low of $42.62 and a 1 year high of $102.10.

Dexcom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The firm had revenue of $184.40 million during the quarter, compared to analysts’ expectations of $172.66 million. Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. The company’s revenue for the quarter was up 29.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.49) earnings per share. research analysts predict that Dexcom will post -0.51 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on DXCM. Canaccord Genuity increased their price objective on shares of Dexcom from $81.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd. ValuEngine upgraded shares of Dexcom from a “hold” rating to a “buy” rating in a research report on Thursday, May 3rd. Oppenheimer increased their price objective on shares of Dexcom from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, May 3rd. BTIG Research restated a “hold” rating on shares of Dexcom in a research report on Thursday, May 3rd. Finally, TheStreet upgraded shares of Dexcom from a “d” rating to a “c-” rating in a research report on Thursday, May 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Dexcom has a consensus rating of “Buy” and a consensus price target of $74.50.

Institutional investors and hedge funds have recently bought and sold shares of the stock. FDx Advisors Inc. grew its stake in Dexcom by 33.3% during the fourth quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock valued at $1,324,000 after acquiring an additional 5,764 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Dexcom by 8.9% during the first quarter. JPMorgan Chase & Co. now owns 2,588,232 shares of the medical device company’s stock valued at $191,943,000 after acquiring an additional 211,250 shares in the last quarter. California Public Employees Retirement System grew its stake in Dexcom by 3.8% during the fourth quarter. California Public Employees Retirement System now owns 134,300 shares of the medical device company’s stock valued at $7,707,000 after acquiring an additional 4,900 shares in the last quarter. Geode Capital Management LLC grew its stake in Dexcom by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 800,783 shares of the medical device company’s stock valued at $45,956,000 after acquiring an additional 8,444 shares in the last quarter. Finally, American International Group Inc. purchased a new position in Dexcom during the fourth quarter valued at $116,000.

Dexcom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Insider Buying and Selling by Quarter for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply